PACS2

Across TCGA pan-cancer cohorts, PACS2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PACS2 data layer compared with 23 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher PACS2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PACS2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

UCEC, CCRCC, and LUAD are the cancer types where PACS2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Tertile	II,III,IV	0.521	1.000	.020	28	view →
CCRCC	OS	Quartile	All	1.000	0.404	.002	27	view →
LUAD	DFS	Median	III,IV	0.326	0.656	.003	8	view →
LSCC	DFS	Quartile	All	0.578	0.892	.004	7	view →
GBM	OS	Quartile	All	0.230	0.619	.020	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PACS2–UCEC (OS)

Open the UCEC breakdown →